To validate the efficacy and safety of azithromycin for the treatment of Chinese patients hospitalized with community-acquired pneumonia (CAP), compared with cefuroxime or the combination of cefuroxime plus oral erythromycin.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
139
intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days
Pfizer Investigational Site
Beijing, China
Pfizer Investigational Site
Shanghai, China
Pfizer Investigational Site
Shanghai, China
Pfizer Investigational Site
Shanghai, China
Pfizer Investigational Site
clinical efficacy (cure or marked improvement)
Time frame: Visit 3 (Day 9 +-1 of treatment)
bacteriological efficacy (eradication)
Time frame: Visit 3
clinical efficacy
Time frame: Visit 4 (8 +/-1 days after treatment)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Shanghai, China